The Gene Analysis Shared Resource (GASR) provides Mayo Clinic Cancer Center researchers efficient, high-quality, cost-effective access to state-of-the-art genomics technologies for studying gene structure and function. Since 2003, the GASR components have been working in a coordinated fashion to provide technical expertise, instrumentation, and coordinated support for DMA sequencing, gene expression profiling, and genotyping. Support for gene expression regulation through RNAi analysis was added in 2007. The services provided by the facility include large-scale, full-service re-sequencing analysis using ABI 3730x1 sequencers, plus comprehensive genotyping and gene transcript analysis using Affymetrix Genechip? technology and Illumina BeadChips. Recent additions to our capabilities include Agilent array CGH and miRNA analysis as well as NextGen sequencing on an Illumina 1G Genome Analyzer Since the last competitive grant renewal, more than 130 Cancer Center members have used the services offered by the GASR and Cancer Center projects account for about two-thirds of all the activity in the GASR. The primary goals of the GASR are to bring cutting edge genomic technologies to Mayo researchers and to do so at an affordable price. This includes, but is not limited to: i. maintaining solid expertise in the use of well-defined commercial platforms for genomic analysis and translating this knowledge into high quality data for Cancer Center members, ii. continued exploration, validation, and implementation of new technologies which will advance the capabilities of the GASR to provide cutting edge genomic assays, iii. enhancement of the utility of archived and fresh clinical samples by developing methodologies which allow for the use of very small amounts of ribonucleic acid from formalin fixed, paraffin embedded (FFPE) and laser-captured microdissected tissues, iv. exploration of new technologies, such as """"""""next generation sequencing,"""""""" and miRNA profiling based on input from users of the GASR for continuous improvement. In addition, we will continue to work closely with bioinformatics and biostatistics to insure seamless interpretation of the data generated through GASR services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-35
Application #
7945030
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-17
Project End
2014-02-28
Budget Start
2009-04-17
Budget End
2010-02-28
Support Year
35
Fiscal Year
2009
Total Cost
$493,515
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications